Compare Annaly Capital Management, Inc. (NLY) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Novavax Inc — how do they compare? Annaly Capital Management, Inc. trades at $22.87 (market cap $16.63B), while Novavax Inc trades at $8.11 (market cap $1.30B). The key difference: Annaly Capital Management, Inc. is far larger — about 12.8× Novavax Inc's market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NLY | NVAX | |
|---|---|---|
Market Cap | $16.63B | $1.30B |
Sector | Financials | Health |
52-Week High | $24.40 | $11.19 |
52-Week Low | $19.96 | $6.22 |
Dividend Yield | 13.22% | — |
Enterprise Value | — | $800.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $22.65, down 1.56% today, with a bullish technical signal and consistent earnings beats. The stock offers a high dividend yield of 13% and trades below the consensus price target of $24.80. Recent Q2 2026 results highlight strong net interest income growth, though mortgage market volatility remains a concern.
Outlook is positive with analyst support (57% buy ratings), but risks include interest rate sensitivity and leverage. The stock presents income opportunity with upside potential, but investors should weigh dividend sustainability against macroeconomic headwinds.
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
